SANSERT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sansert, and when can generic versions of Sansert launch?
Sansert is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SANSERT is methysergide maleate. Additional details are available on the methysergide maleate profile page.
Summary for SANSERT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 20 |
Clinical Trials: | 1 |
Patent Applications: | 3,771 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SANSERT at DailyMed |
Recent Clinical Trials for SANSERT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Stanford University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for SANSERT
US Patents and Regulatory Information for SANSERT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SANSERT | methysergide maleate | TABLET;ORAL | 012516-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |